{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-024479","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.704628+00:00","generated_at":"2026-06-21T23:09:58.669893+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Spruce Biosciences Q3 net loss $11.4M; cash $90.4M; enrollment milestones updated","bullets":["Cash, cash equivalents and investments totaled $90.4M as of Sept 30, 2022.","Net loss for Q3 2022 was $11.4M, flat YoY; R&D expenses $8.8M vs $8.6M.","CAHmelia-203 approaching 50% enrollment; CAHmelia-204 surpassed 25% enrollment.","Appointed Saba Sile, M.D., as VP of Clinical Development from Horizon Therapeutics.","Topline results expected: PCOS trial H1 2023; CAHmelia-203 H2 2023; CAHmelia-204 H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-024479","json":"https://secwatch.observer/filing/0000950170-22-024479.json","markdown":"https://secwatch.observer/filing/0000950170-22-024479.md","text":"https://secwatch.observer/filing/0000950170-22-024479.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/0000950170-22-024479-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/sprb-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T23:09:58.669893+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8847170898bb9fbfd2cbfe6a69faa66784d665ea","claim":"SPRUCE BIOSCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $11.4 million.","evidence_excerpt":"Net loss for the three and nine months ended September 30, 2022 was $11.4 million and $35.0 million, respectively, compared to $11.4 million and $33.1 million, respectively, for the same periods in 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017022024479/0000950170-22-024479-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"$11.4 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}